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Abstract
Background: In a transgenic mouse model of Alzheimer disease (AD), cleavage of the amyloid precursor
protein (APP) by the α-secretase ADAM10 prevented amyloid plaque formation, and alleviated cognitive
deficits. Furthermore, ADAM10 overexpression increased the cortical synaptogenesis. These results
suggest that upregulation of ADAM10 in the brain has beneficial effects on AD pathology.
Results: To assess the influence of ADAM10 on the gene expression profile in the brain, we performed
a microarray analysis using RNA isolated from brains of five months old mice overexpressing either the
α-secretase ADAM10, or a dominant-negative mutant (dn) of this enzyme. As compared to non-transgenic
wild-type mice, in ADAM10 transgenic mice 355 genes, and in dnADAM10 mice 143 genes were found to
be differentially expressed. A higher number of genes was differentially regulated in double-transgenic
mouse strains additionally expressing the human APP[V717I] mutant.
Overexpression of proteolytically active ADAM10 affected several physiological pathways, such as cell
communication, nervous system development, neuron projection as well as synaptic transmission.
Although ADAM10 has been implicated in Notch and β-catenin signaling, no significant changes in the
respective target genes were observed in adult ADAM10 transgenic mice.
Real-time RT-PCR confirmed a downregulation of genes coding for the inflammation-associated proteins
S100a8 and S100a9 induced by moderate ADAM10 overexpression. Overexpression of the dominant-
negative form dnADAM10 led to a significant increase in the expression of the fatty acid-binding protein
Fabp7, which also has been found in higher amounts in brains of Down syndrome patients.
Conclusion:  In general, there was only a moderate alteration of gene expression in ADAM10
overexpressing mice. Genes coding for pro-inflammatory or pro-apoptotic proteins were not over-
represented among differentially regulated genes. Even a decrease of inflammation markers was observed.
These results are further supportive for the strategy to treat AD by increasing the α-secretase activity.
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Background
Accumulation of amyloid β-peptides (Aβ) in the brain is
believed to contribute to the development of Alzheimer
disease (AD). Soluble oligomeric forms of Aβ are neuro-
toxic [1-3]. Aβ, a 40–43 amino acid-comprising proteolyt-
ical fragment of the amyloid precursor protein (APP), is
released from APP by sequential cleavages via β- and γ-
secretases. However, the predominant route of APP
processing consists of successive cleavages by α- and γ-
secretases. Alpha-secretase attacks APP inside the Aβ
sequence, and therefore prevents formation of neurotoxic
Aβ. In addition, the soluble N-terminal domain of APP
(APPsα) is released, which has neurotrophic and neuro-
protective properties [4,5], and enhances LTP [6]. In
behavioral paradigms, APPsα was demonstrated to
improve memory in normal and amnesic mice [7].
Reduced amounts of APPsα were detected in the cerebro-
spinal fluid of AD patients [8,9].
Proteinases of the ADAM (adisintegrin and metalloprotei-
nase) family are main candidates for physiologically rele-
vant α-secretases, and we demonstrated that ADAM10 has
α-secretase activity in vitro and in cultured cells [10].
ADAM10-deficient mice have been generated [11], but
their early lethality at day E9.5 prevents a reliable analysis
of ADAM10's α-secretase function in vivo, especially in
neuronal cells.
To investigate whether an increase in activity of putative
α-secretases in vivo prevents plaque formation and cogni-
tive deficits, we generated transgenic mice overexpressing
either the α-secretase ADAM10 (ADAM10 mice) or the
catalytically inactive ADAM10[E384A] mutant (dnADAM10
mice) [12]. Neuronal overexpression of ADAM10 had no
detrimental effects on ADAM10 single-transgenic mice:
these animals exhibited normal behavioral abilities [13].
We found that a moderate neuronal overexpression of
ADAM10 in mice carrying the human APP[V717I] mutation
(ADAM10/APP[V717I]  mice) increased the secretion of
APPsα, reduced the formation of Aβ peptides, and pre-
vented their deposition in plaques. Functionally,
impaired long-term potentiation and cognitive deficits
were alleviated. Expression of dominant-negative
ADAM10 [E384A] in APP[V717I] mice (dnADAM10/APP[V717I]
mice) led to reduction of APPsα and to enhancement of
the number and size of amyloid plaques in the brain [12].
Histological analyses of mono-transgenic ADAM10 mice
revealed an increase in cortical cholinergic, glutamatergic
and GABAergic presynaptic bouton densities in 8 months
old mice; the cholinergic presynaptic bouton density
remained elevated even during aging in ADAM10 mice
[14].
In addition to their metalloproteinase domain, ADAMs
contain a disintegrin domain as a modulator of cell-cell
and cell-matrix interactions [15]. As ADAM10 itself has
been reported to be a substrate for ectodomain shedding
by ADAM9 and subsequent cleavage by γ-secretase, the C-
terminus of ADAM10 may represent a Notch-like signal-
ing molecule [16]. Thus, independent of the catalytic
activity of ADAM10, which has been implicated in Notch
and  β-catenin signaling, ADAM10 may also modulate
gene expression via other domains.
To analyze the influence of ADAM10 and its dominant-
negative form (dnADAM10) on the gene expression pro-
file of the central nervous system (CNS), we investigated
ADAM10 and dnADAM10 mice. We included in our study
the double-transgenics ADAM10/APP[V717I]  and
dnADAM10/APP[V717I]. Since APP[V717I] mice show early
phenotype changes (between months 4 and 7), we inves-
tigated the gene expression in 5 months old mice.
Methods
Animals
Animal husbandry was performed in accord with the
guidelines of the German Council on Animal Care. All
mouse strains (strain background FVB/N) analyzed in this
study have been described previously [12]. The expression
level of transgenic mature ADAM10 is 30% above endog-
enous levels and in dnADAM10 mice the expression of the
catalytically inactive ADAM10 mutant is sevenfold above
endogenous ADAM10 [12]. ADAM10 activity was deter-
mined in previous studies [12,17] by quantitation of the
APP cleavage product APPsα. In ADAM10 overexpressing
mice the catalytic activity of ADAM10 against its substrate
APP[V717I] was increased to about 250%. In mice overex-
pressing dnADAM10, the endogenous APP[V717I] cleavage
activity was reduced to about 25% as compared to
APP[V717I] mice [12].
For the first experimental series of the present study,
female ADAM10, dnADAM10 and FVB/N wild-type mice
were investigated; for the second series, female and male
ADAM10/APP[V717I], dnADAM10/APP[V717I] and APP[V717I]
mice were compared. In each case, brains of three 5
months old animals of each group were dissected and
stored in RNA-later (Qiagen, Hilden, Germany) at -80°C
to prevent RNA degradation.
RNA preparation and microarray analyses
Total RNA from whole mouse brains was isolated by using
the RNeasy Kit (Qiagen, Hilden, Germany), including on-
column DNase I digestion according to the manufac-
turer's recommendations. The quality of isolated RNA was
controlled by the Lab-on-Chip-System Bioanalyser 2100
(Agilent Technologies Inc., Palo Alto, CA, USA).
The expression-profiling analysis for mono-transgenic
mice (ADAM10, dnADAM10 mice and non-transgenic
FVB/N control animals) was carried out at RZPD (Berlin,BMC Genomics 2009, 10:66 http://www.biomedcentral.com/1471-2164/10/66
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Germany). Samples from double-transgenic mice
(ADAM10/APP[V717I, dnADAM10/APP[V717I]  and mono-
transgenic APP[V717I] control mice) were analyzed at the
Microarray Facility (Tübingen, Germany). In all cases, the
Mouse Genome 430 2.0 Array (Affymetrix, Santa Clara,
CA, USA) containing 45000 probe sets of 34000 genes
was used for mRNA expression profiling.
Statistical analysis and gene annotations
For the first series (mono-transgenic mice) 9 gene chip
arrays and for the second series (double-transgenic mice)
18 gene chip arrays were analyzed. Data mining was per-
formed by using the ChipInspector analysis software
(Genomatix, Munich, Germany), which identifies signifi-
cant changes based on single probes. The corresponding
transcripts were then assigned after a user-defined number
of significant probes. For all analyses, a transcript coverage
greater than three probes was chosen. By this strategy,
annotation errors and errors caused by the existence of
alternative transcripts are reduced.
After total intensity normalization of each array, signifi-
cantly changed genes were determined by significance
analysis of microarrays (SAM) [18], using the exhaustive
comparison mode at a false discovery rate (FDR) of 0.0%
for double-transgenic, and 0.5% for mono-transgenic
mice. For separate analysis of samples from double-trans-
genic female and male mice, a FDR of 1.3% was chosen.
The resulting gene lists were restricted to the 600 most
strongly regulated genes (up- as well as downregulated
genes).
Regulated genes were then analyzed with the Bibliosphere
software (Version 5.02; Genomatix, Munich, Germany)
and mapped to Gene Ontology (GO) trees in order to
identify their biological function. For identification of
over-represented GO terms, the Bibliosphere software cal-
culates a z-score for each term. The z-score represents the
difference between observed and expected annotations,
and is normalized to the standard deviation of a hyperge-
ometric distribution. Only GO terms with a z-score >
1.96, which corresponds to a p-value of 0.05, have been
considered.
To identify transcripts which are affected by ADAM10 and
dnADAM10 overexpression in mono- and double-trans-
genic mice, we generated Venn diagrams with SAM-based
gene lists. The expression profile of selected significantly
regulated genes from microarrays was represented by heat
maps using the R statistical software http://www.r-
project.org. Hierarchical clustering was applied to investi-
gate whether expression values can be separated according
to experimental groups. In this study, two heat maps were
generated: one compared the expression profiles of genes
in ADAM10 and dnADAM10 mono-transgenic mice, as
well as in FVB/N non-transgenic control mice; a second
one compared the expression profiles of double-transgen-
ics and APP[V717I] mice.
Because the two series of expression arrays were measured
in different laboratories, a global normalization proce-
dure was needed to make them comparable. The default
background noise adjustment, provided by the Affymetrix
system, is based on the difference of perfect matching
probes (PM) minus mismatching probes (MM). Due to
unspecific binding, the global background adjustment
method robust multi-array average (RMA) expression
measure, which ignores the MM intensities, has been
developed [19]. Because RMA adjustment does not com-
pletely remove unspecific intensities [20], an enhanced
method denoted GeneChip RMA (GCRMA) has been
designed [21] which considers the sequence of probes.
We performed background adjustment as well as quantile
normalization for all data sets (raw format, cell files) with
the GCRMA method (standard settings) by using the CAR-
MAweb interface [22]. Subsequently, an unpaired two-
tailed Student's t-test was applied for each respective gene
to determine whether it is differentially expressed in the
two sample groups. Since microarray analysis operates
with large numbers of multiple comparisons, a false dis-
covery rate-controlling method has to be applied. There-
fore, by using the Benjamini-Hochberg (BH) method,
adjusted p-values were calculated [23].
The GCRMA method is also appropriate for detection of
minor changes in gene expression, and was required for
comparative analysis of mono- and double-transgenic
mice, due to the low intensities of the microarrays from
the first series (mono-transgenic mice) as compared to
those of the second series (double-transgenic mice). By
comparing data derived from mono- and double-trans-
genic mice, we analyzed global biological trends of
ADAM10 and dnADAM10 overexpression in FVB/N and
FVB/N APP[V717I] strain backgrounds.
To identify transcripts which were commonly affected by
APP[V717I]overexpression in all double-transgenic mice,
we generated a Venn diagram with GCRMA-based gene
lists (BH<0.005).
Quantitative real-time RT-PCR
A two-step real-time reverse transcription (RT)-PCR was
used to measure the expression of candidate genes. Iso-
lated total RNA (1 μg) was used to synthesize cDNA in a
20 μl reaction with the QuantiTect Reverse Transcription
Kit (Qiagen, Hilden, Germany) according to the manufac-
turer's manual. By adding water, the reaction volume was
subsequently increased to 500 μl. Real-time RT-PCR was
carried out in 96-well plates, using the 7000 ABI prismBMC Genomics 2009, 10:66 http://www.biomedcentral.com/1471-2164/10/66
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sequence detection system (Applied Biosystems, Darm-
stadt, Germany) and QuantiTect Primer Assays (Qiagen,
Hilden, Germany). The primers for selected candidate
genes are listed in table 1.
Real-time RT-PCR reactions in a volume of 30 μl were per-
formed in duplicate or triplicate under the following con-
ditions: 5 μl of diluted cDNA (see above), 15 μl 2×
QuantiTect PCR master mix (Qiagen, Hilden, Germany)
and 300 nM of respective primer pair. After the initial
denaturing and enzyme activation step (95°C for 15
min), 40 cycles (94°C for 15s, 55°C for 30s, and 72°C for
30s) were performed. A single DNA melting profile was
observed in dissociation assay conditions demonstrating
amplification of a unique product free of primer dimers.
For detection of Hes5 in 15 day old mice a one step Real-
time RT-PCR was performed using the QuantiTect-SYBR-
Green One-Step-RT PCR-Kit (Qiagen, Hilden, Germany)
and 250 ng RNA in a reaction volume of 30 μl. The spe-
cific primer pair was as follows: Hes5RT_for
5'GAAAAACCGACTGCGGAAGCC3' and Hes5RT_rev
5'ACGGCCATCTCCAGGATGTC3'.
For data analysis, the threshold cycle (Ct) which indicates
the relative abundance of a particular transcript, was cal-
culated. Standard curves were generated by amplification
of serially diluted cDNA. According to this method, the
amount of all relevant genes was normalized to the
amount of endogenous GAPDH present in the same sam-
ple. Measured values from control samples (non-trans-
genic FVB/N mice or mono-transgenic APP[V717I] mice)
were set to 100%. Changes in gene expression are pre-
sented as the mean of alteration ± SD. The data were ana-
lyzed for statistical significance using one-way ANOVA (*,
p < 0.05; **, p < 0.01; ***, p < 0.001).
Western blotting
Mouse brain tissue was stored on dry ice immediately
after dissection. Ice-cold TRIS buffer (20 mM Tris/HCl, pH
8.5) containing proteinase inhibitors (Inhibitor complete
mini, Roche Diagnostics Corp., Mannheim, Germany)
was added, and tissue was homogenized in a tissue lyser
(Qiagen, Hilden, Germany). The supernatants resulting
from centrifugation at 34000 rpm for 1.75 hours were
separated on 14% SDS-gels and transferred to nitrocellu-
lose membrane by tank blot system (40 μg protein per
sample). For the detection and quantification of soluble
FABP7 antibody AB9558 (Chemicon, Temecula, USA),
and the appropriate horseradish peroxidase-coupled sec-
ondary antibody (Pierce, Rockford, USA) were used.
ELISA
Hemispheres of mouse brain were weighed, proteins
extracted and calprotectin (S100a8/a9) was quantified as
recommended by the ELISA manufacturer (Immundiag-
nostik, Bensheim, Germany). In brief, tissue was homog-
enized in extraction buffer for 2 min at 20 Hz in a tissue
lyzer and extraction was performed for 20 min at 4°C
under agitation. After centrifugation (14000 rpm, 15 min)
the supernatant and protein standards were added to
microtiter plates in a total volume of 100 μl in duplicates.
Incubation of the plate and measurement of optical den-
sities at 405 nm were performed following the manufac-
turer's instructions. The relative amount of calprotectin
was calculated by division of background-corrected values
by wet tissue weight.
Results
Microarray analysis of gene regulation in ADAM10-
transgenic mice
We performed microarray analysis with cDNA transcribed
from total RNA of the brains of mice aged five months.
Mono-transgenic ADAM10 as well as dnADAM10 mice
were investigated in comparison to non-transgenic FVB/N
wild-type mice (n = 3 females), to analyze the influence of
the α-secretase ADAM10 or its catalytically inactive form
(dnADAM10) on the gene expression profile of the CNS.
To elucidate the effect of ADAM10 and dnADAM10 on
gene expression in an APP background, we compared
samples derived from double-transgenic ADAM10/
Table 1: QuantiTect Primer Assays (Qiagen, Hilden, Germany)
Gene name Gene ID Assay
ADAM10 11487 Mm_Adam10_1_SG
Fatty acid binding protein 7 12140 Mm_Fabp7_1_SG
Calcium binding protein S100a9 20202 Mm_S100a9_1_SG
Calcium binding protein S100a8 20201 Mm_S100a8_1_SG
Glutamate receptor, ionotropic, AMPA1 14799 Mm_Gria_1_SG
Glutamate receptor, ionotropic, AMPA2 14800 Mm_Gria2_1_SG
Low density lipoprotein receptor-related protein 1 16971 Mm_Lrp1_1_SG
Very low density lipoprotein receptor 22359 Mm_Vldlr_1_SG
Microtubule-associated protein tau 17762 Mm_Mapt_1_SG
Neuroligin 1 192167 Mm_Nlgn1_1_SG
GAPDH 14433 Mm_Gapdh_2_SGBMC Genomics 2009, 10:66 http://www.biomedcentral.com/1471-2164/10/66
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APP[V717I]  and dnADAM10/APP[V717I]  mice with those
from mono-transgenic APP[V717I]  mice. Because we
wanted to test whether the modulation of ADAM10 activ-
ity might be a risk to the adult organism in respect to
future therapeutic approaches, we chose 5 months old
mice for our investigations. At this age, APP[V717I] animals
show cognitive deficits, whereas amyloid plaque forma-
tion occurs several months later [24].
The SAM plots in Fig. 1 represent the distribution of all
probe signals on the microarray chip. Depending on the
statistical stringency (FDR, delta) as represented by the red
lines, significant probes are selected. Probe signals
between the red lines are not significant, signals above the
upper line correspond to significantly upregulated genes;
signals below the lower line correspond to significantly
downregulated genes. Tables 2 and 3 show the numbers
of these differentially expressed genes.
The comparison of samples from ADAM10 and FVB/N
mice revealed 355 differentially expressed genes: 300
genes were up- and 55 genes were downregulated. In
dnADAM10 mice, the number of regulated genes was
lower; as compared to FVB/N mice, 143 genes were differ-
entially expressed. Among these, 50 genes were up- and
93 genes downregulated (Tab. 2).
Against the background of APP[V717I] overexpression, gen-
erally more genes were found to be differentially
expressed. As compared to APP[V717I] mice, 592 genes (295
up- and 297 downregulated) were differentially expressed
in ADAM10/APP[V717I] mice, and more than 600 genes in
dnADAM10/APP[V717I] animals (Tab. 3). In the latter, the
number of significantly regulated genes was restricted to
600, including the highest up- and downregulated genes.
For the complete list of significantly regulated genes, see
Additional file 1, Tables S1-S4. The data presented in this
publication have been deposited in NCBI's Gene Expres-
sion Omnibus (GEO), and are accessible by the GEO
Series accession numbers GSE10908 and GPL1261 http:/
/www.ncbi.nlm.nih.gov/geo/info/faq.html#deposit.
For detection of transcripts that were commonly regulated
by either ADAM10 or dnADAM10 overexpression in
mono- and double-transgenic mice, Venn diagrams were
generated with SAM-based gene lists (Fig. 2). The compar-
ison of ADAM10 versus FVB/N (355 genes), and
ADAM10/APP[V717I] versus APP[V717I] (592 genes) revealed
29 genes which were regulated by ADAM10 overexpres-
sion in either mono- or double-transgenic mice (Addi-
tional file 1, Tab. S5). When dnADAM10 versus FVB/N
(143 genes) and dnADAM10/APP[V717I] versus APP[V717I],
were compared, only eight genes were identified to be
commonly regulated by dnADAM10 overexpression
(Additional file 1, Tab. S6). This result indicates that the
genetic background strongly influences the effect of
ADAM10 on gene expression.
Common genetic profile in mono- and double-transgenic 
animals
Heat maps (Fig. 3) indicate that the chips of each series
had their own characteristic genetic profile. For heat
maps, genes of special interest were chosen (mono-trans-
genic mice: Adam10, Fabp7, S100a8, S100a9, Nlgn1;
double-transgenic mice: Mapt, Gria1, Vldlr, Lrp1, Bace1,
Psen1, Psen2, ApoE). The heat map in Fig. 3A reveals that
in mice overexpressing bovine ADAM10, approximately
the same amount of murine Adam10 is expressed as com-
pared to wild-type mice (nearly all over yellow coloring).
Fabp7 is distinctly higher expressed in all dnADAM10
mice (red color) in contrast to wild-type mice (orange
color). The expression of Nlgn1 in ADAM10 and
dnADAM10 mice is higher (yellow to green) than in FVB/
N mice (green color)). Finally, S100a8 and S100a9 show
lower expression in ADAM10 and dnADAM10 mice (blue
color) in relation to FVB/N wild-type mice (yellow to
blue). These results are in accordance with the observa-
tions made by the real-time RT-PCR as described below.
Furthermore, hierarchical clustering showed that the
expression profiles of the mono-transgenic mouse genes
are separated to the original conditions. In the case of heat
map in Fig. 3B, the small differences in the expression of
Mapt, Gria1, Vldlr and Lrp1 are fitting to the results of
real-time RT-PCR analyses as described below. Hierarchi-
cal clustering revealed that the expression profiles of dou-
ble-transgenic mice genes are not clearly clustered
according to the experimental settings, presumably due to
the more complex conditions caused by APP overexpres-
sion. Also, a clear distinction between male and female
mice could not be observed.
Table 2: Numbers of significantly regulated genes in mono-transgenic mice (5 months, 3 females per group) restricted by the given d-
values.
Mouse Genome 430 2.0 Array (Affymetrix)
45 000 probe sets, 39 000 transcripts, 34 000 characterized
ADAM10 versus FVB/N (wild-type)
355 genes, FDR = 0.5%
dnADAM10 versus FVB/N (wild-type)








(d-value < -1.36)BMC Genomics 2009, 10:66 http://www.biomedcentral.com/1471-2164/10/66
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ADAM10-regulated biological pathways
For pathway analysis, the complete gene lists were ana-
lyzed with the Bibliosphere software (Genomatix) and
mapped to Gene Ontology (GO) trees.
Functional groups are only listed when their z-score of
individual GO-categories is higher than 1.96. With respect
to the known cellular function of disintegrin metallopro-
teases in general, and the α-secretase activity of ADAM10
in particular, we investigated biological processes includ-
ing cell communication (GO:0007154), nervous system
development (GO:0007399), cell adhesion
(GO:0007155) and cell death (GO:0008219). Further-
more, we examined neuron projection (GO:0043005),
synaptic junction (GO:0045202) and transmission
(GO:0007268). At the molecular level, we focused on
Table 3: Numbers of significantly regulated genes in double-transgenic mice (5 months, 3 females and 3 males per group) restricted by 
the given d-values.
Mouse Genome 430 2.0 Array (Affymetrix)
45 000 probe sets, 39 000 transcripts, 34 000 characterized
ADAM10/APP[V717I] versus APP[V717I]
592 genes, FDR = 0.0%
dnADAM10/APP[V717I] versus APP[V717I]









Significance analysis of microarrays Figure 1
Significance analysis of microarrays. The SAM plots represent the differentially expressed genes of mono-transgenic (A 
and B with FDR 0.5), and double-transgenic mice (C and D with FDR 0.0). The Delta parameter, represented by red lines, 
defines the significance field (-1.72/+2.23 (A: ADAM10 versus FVB/N), -1.36/+1.43 (B: dnADAM10 versus FVB/N), -1.56/+2.06 
(C: ADAM10/APP[V717I] versus APP[V717I]), -2.85/+3.29 (D: dnADAM10/APP[V717I] versus APP[V717I])). Shown above the upper 
line are the genes upregulated significantly, and below the lower line the genes downregulated significantly.
A
C D
BBMC Genomics 2009, 10:66 http://www.biomedcentral.com/1471-2164/10/66
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receptor binding (GO:0005102) and receptor activity
(GO:0004872) (Tab. 4, 5, 6, 7).
The highest number of regulated genes in ADAM10
mono-transgenic mice (Tab. 4) belonged to the category
of cell communication (53 genes), followed by the catego-
ries of synaptic junction and transmission (16 genes), and
of nervous system development (15 genes). In
dnADAM10 mice, fewer genes were found especially in
the category of cell communication (15 genes).
In mono-transgenic mice, genes in the functional groups
of inflammation or cell death were not over-represented
(z-score < 1.96). In contrast, the category of cell death was
over-represented in both double-transgenic mouse lines
(Tab. 6 and 7), probably due to APP[V717I] overexpression.
The major difference in the two double-transgenic lines
was the 3-fold higher number of regulated genes in the
category of cell communication in the ADAM10/
APP[V717I] double-transgenic line (96 genes), as compared
to dnADAM10/APP[V717I] mice.
The results show that overexpression of proteolytically
active ADAM10 generally influences cellular communica-
tion in mice, independently of their genetic background.
One example for a regulated gene of this category is the
calcium/calmodulin-dependent protein kinase II alpha
(Camk2α), which is upregulated in mono-transgenic
ADAM10 mice (Tab. 4) and downregulated in
dnADAM10 mice (Tab. 5). Other genes of this category
are the LDL receptor-related protein (Lrp1, Tab. 4, Addi-
tional file 1, Table S1), neuroligin (Nlgn1, Tab. 4, 6) and
the very low density lipoprotein receptor (Vldlr, Addi-
tional file 1, Table S3).
ADAM10 overexpression has been shown to increase cor-
tical synaptogenesis as revealed by immunohistochemis-
try [14]. Accordingly, here we confirmed these results on
the mRNA level for two neurotransmitter systems: the
glutamate receptor Gria3 and the glutamic acid decarbox-
ylase 2 (Gad2) as well as the GABA-A receptor subunit
alpha 4 (Gabra4). These are examples of up-regulated
genes within the category of synaptic junction and trans-
mission (Tab. 4).
Because ADAM10 has proteolytical activity, we were also
interested in gene expression of putative ADAM10 sub-
strates like APP and Egfr (Tab. 8). Their expressions were
not regulated in mono-transgenic mice, and therefore
they are not listed in tables 4, 5, 6, 7 and tables S1-S4.
Notch-1 expression was not changed in mice aged 5
months and its target gene Hes5 was only slightly affected
in ADAM10 mice (Tab. 4). However, it has been reported
that the ADAM10 knock out leads to severely affected
Notch signaling and embryonic lethality at day 9.5 [11].
As in our transgenic animals ADAM10 was under control
of the postnatal active neuron-specific mouse Thy 1-pro-
moter, ADAM10 has no effect during embryogenesis. To
examine whether the lack of influence of ADAM10 on the
Notch pathway in our transgenic mice is due to the rela-
tive late stage (5 months) of investigation, we analyzed
the expression of the Notch-1 target gene Hes5 in trans-
genic mice aged 15 days (Fig. 4): about 40% induction
was observed in the ADAM10 overexpressing mice and a
reduction of about 50% in the dnADAM10 transgenic
mice.
In addition, we found that overexpression of ADAM10
and dnADAM10 did not affect expression of either endog-
Venn diagrams with SAM-based gene lists of mono- and double-transgenic mice Figure 2
Venn diagrams with SAM-based gene lists of mono- and double-transgenic mice. Venn diagram I (ADAM10 versus 
FVB/N (A) is compared with ADAM10/APP[V717I] versus APP[V717I] (B)), and Venn diagram II (dnADAM10 versus FVB/N (A) is 
compared with dnADAM10/APP[V717I] versus APP[V717I] (B)), generated by a custom-written Perl-script, show the effects of the 
overexpression of ADAM10 and dnADAM10 in mono- and double-transgenic mice. The numbers in the space of overlapping 
circles represent the number of transcripts that were affected in both mouse lines.BMC Genomics 2009, 10:66 http://www.biomedcentral.com/1471-2164/10/66
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Heat map representing the clustering of genes in mono- and double transgenic mice Figure 3
Heat map representing the clustering of genes in mono- and double transgenic mice. A) ADAM10, dnADAM10 
and FVB/N mice; B) AD10/APP[V717I], dnAD10/APP[V717I], and APP[V717I] mice. Selected significantly regulated genes on individual 
chips are shown. The upper graph (I) represents the hierarchical clustering, the colored scales (II) the difference in gene 
expression. Unsupervised cluster analysis showed that the expression profiles of mono-transgenic mouse genes (A) cluster 
according to the experimental conditions. In case of double-transgenic mice (B), cluster analysis revealed a more rough agree-
ment in the discrimination of gene expression with experimental groups. The blue (lower expression) to red (higher expres-
sion) color scale indicates 2-based logarithms of the mean expression values of the single probes after ChipInspector 
normalization (Genomatix, Munich, Germany).
A  mono-transgenic mice
B  double-transgenic miceBMC Genomics 2009, 10:66 http://www.biomedcentral.com/1471-2164/10/66
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Table 4: Significantly regulated genes in mono-transgenic ADAM10 mice in relation to FVB/N wild-type mice
Gene ID Gene symbol Description Fold change log ratio d-value Functional groups
27360 Add3 adducin 3 (gamma) 1.519 0.603 2.841 receptor binding and activity
68465 Adipor2 adiponectin receptor 2 1.365 0.449 2.294 cell communication
11658 Alcam activated leukocyte cell adhesion 
molecule
1.471 0.557 2.298 nervous system development; 
neuron projection
211673 Arfgef1 ADP-ribosylation factor guanine 
nucleotide-exchange factor 1
(brefeldin A-inhibited)
1.503 0.588 2.644 cell communication
11855 Arhgap5 Rho GTPase activating protein 5 1.621 0.697 2.526 cell communication
98660 Atp1a2 ATPase, Na+/K+ transporting, alpha 2 
polypeptide
0.792 -0.337 -1.972 cell communication; synapse
11941 Atp2b2 ATPase, Ca++ transporting, plasma 
membrane 2
1.734 0.794 2.717 cell communication; nervous system 
development; receptor binding and 
activity; synapse
22589 Atrx alpha thalassemia/mental retardation 
syndrome X-linked homolog (human)
1.507 0.592 2.876 nervous system development
30948 Bin1 bridging integrator 1 1.451 0.537 2.318 cell communication; synapse
12298 Cacnb4 calcium channel, voltage-dependent, 
beta 4 subunit
1.800 0.848 2.913 cell communication; synapse
12322 Camk2a calcium/calmodulin-dependent protein 
kinase II alpha
1.779 0.831 2.547 cell communication; receptor 
binding and activity; synapse
16149 Cd74 CD74 antigen (invariant polypeptide of 
major histocompatibility complex, class 
II antigen-associated)
0.724 -0.466 -2.270 cell communication; cell death
212285 Centd1 centaurin, delta 1 1.569 0.650 2.530 cell communication
12633 Cflar CASP8 and FADD-like apoptosis 
regulator
1.393 0.478 2.497 cell death
12704 Cit citron 1.476 0.562 2.405 cell communication; nervous system 
development
12803 Cntf ciliary neurotrophic factor 1.496 0.581 2.355 cell communication; nervous system 
development
70086 Cysltr2 cysteinyl leukotriene receptor 2 1.307 0.386 2.251 cell communication
13618 Ednrb endothelin receptor type B 1.364 0.448 2.506 cell communication; nervous system 
development
13838 Epha4 Eph receptor A4 1.622 0.698 2.439 cell communication; nervous system 
development
67456 Ergic2 ERGIC and golgi 2 1.367 0.451 2.316 cell communication; synapse
14397 Gabra4 gamma-aminobutyric acid (GABA-A) 
receptor, subunit alpha 4
1.542 0.625 2.316 cell communication; synapse
14417 Gad2 glutamic acid decarboxylase 2 1.636 0.710 3.290 cell communication; neuron 
projection; synapse
14674 Gna13 guanine nucleotide binding protein, 
alpha 13
1.502 0.587 2.257 cell communication
14677 Gnai1 guanine nucleotide binding protein, 
alpha inhibiting 1
1.576 0.656 2.911 cell communication
14680 Gnal guanine nucleotide binding protein, 
alpha stimulating, olfactory type
1.598 0.676 3.061 cell communication
53623 Gria3 glutamate receptor, ionotropic, 
AMPA3 (alpha 3)
1.480 0.566 2.388 synapse
56637 Gsk3b glycogen synthase kinase 3 beta 1.540 0.623 2.382 cell communication; cell death
15208 Hes5 hairy and enhancer of split 5 
(Drosophila)
0.749 -0.416 -1.800 nervous system development
16419 Itgb5 integrin beta 5 0.786 -0.347 -2.185 cell adhesion; cell communication
16510 Kcnh1 potassium voltage-gated channel, 
subfamily H (eag-related), member 1
1.398 0.483 2.291 cell communication; receptor 
binding and activity
16561 Kif1b kinesin family member 1B 1.555 0.637 2.573 cell communication; synapse
16573 Kif5b kinesin family member 5B 1.904 0.929 3.186 neuron projection; synapse
16574 Kif5c kinesin family member 5C 1.656 0.728 2.463 nervous system development; 
neuron projection; synapse
110829 Lims1 LIM and senescent cell antigen-like 
domains 1
1.533 0.616 2.309 cell adhesion
108030 Lin7a lin-7 homolog A (C. elegans) 1.346 0.429 2.260 cell communication; synapse
319387 Lphn3 latrophilin 3 1.295 0.373 2.344 cell communicationBMC Genomics 2009, 10:66 http://www.biomedcentral.com/1471-2164/10/66
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enous Adam10 or of other putative α-secretases like
Adam9, Adam17 and Bace2 in adult mice. In general, the
observed alteration of gene expression was low in all ana-
lyzed mouse lines (see the fold changes in Tab. 4, 5, 6, 7).
Alzheimer disease-related genes regulated by ADAM10
The GeneCards database (Weizmann Institute of Science,
Version 2.36), which contains 934 genes connected with
AD (gene list see Additional file 1, Tab. S7), was used for
identification of AD-related genes regulated by ADAM10.
In ADAM10 mice, 25 AD genes (7% of 355 genes) were
differently regulated, and in dnADAM10 mice 13 AD
genes (9% of 143 genes) (Fig. 5) were altered including
genes involved in cholesterol and lipid homeostasis, like
Lrp1, Vldlr, and fatty acid-binding protein Fabp7. Other
16971 Lrp1 low density lipoprotein receptor-
related protein 1
0.707 -0.500 -2.139 cell communication
16998 Ltbp3 latent transforming growth factor beta 
binding protein 3
0.791 -0.338 -2.180 cell communication; receptor 
binding and activity
50791 Magi2 membrane associated guanylate kinase, 
WW and PDZ domain containing 2
1.426 0.512 2.399 cell communication
192167 Nlgn1 neuroligin 1 1.518 0.602 2.386 cell communication; nervous system 
development; synapse
18549 Pcsk2 proprotein convertase subtilisin/kexin 
type 2
1.492 0.577 2.393 nervous system development
18573 Pde1a phosphodiesterase 1A, calmodulin-
dependent
1.796 0.845 3.130 cell communication; receptor 
binding and activity
18596 Pdgfrb platelet derived growth factor 
receptor, beta polypeptide
0.800 -0.322 -1.867 cell communication
18613 Pecam1 platelet/endothelial cell adhesion 
molecule 1
0.778 -0.363 -2.093 cell communication
18795 Plcb1 phospholipase C, beta 1 1.652 0.724 3.345 cell communication
18798 Plcb4 phospholipase C, beta 4 1.480 0.566 2.451 cell communication
242083 Ppm1l protein phosphatase 1 (formerly 2C)-
like
1.604 0.682 2.277 cell communication
26932 Ppp2r5e protein phosphatase 2, regulatory 
subunit B (B56), epsilon isoform
1.578 0.658 2.298 cell communication
19281 Ptprt protein tyrosine phosphatase, receptor 
type, T
1.409 0.495 2.354 cell communication
19328 Rab12 RAB12, member RAS oncogene family 1.250 0.322 2.259 cell communication
270192 Rab6b RAB6B, member RAS oncogene family 1.696 0.762 2.837 cell communication; synapse
56044 Rala v-ral simian leukemia viral oncogene 
homolog A (ras related)
1.582 0.662 2.544 cell communication
54409 Ramp2 receptor (calcitonin) activity modifying 
protein 2
1.693 0.760 2.640 cell communication
218397 Rasa1 RAS p21 protein activator 1 1.428 0.514 2.266 cell adhesion; cell communication; 
cell death
19737 Rgs5 regulator of G-protein signaling 5 1.677 0.746 2.390 cell communication
19894 Rph3a rabphilin 3A 1.470 0.556 2.352 synapse
68585 Rtn4 reticulon 4 1.542 0.625 2.344 cell death; nervous system 
development
20202 S100a9 S100 calcium binding protein A9 0.668 -0.582 -2.146 cell communication
20377 Sfrp1 secreted frizzled-related sequence 
protein 1
0.793 -0.335 -1.730 cell communication
239250 Slitrk6 SLIT and NTRK-like family, member 6 1.324 0.405 2.293 nervous system development
93761 Smarca1 SWI/SNF related, matrix associated, 
actin dependent regulator of 
chromatin, subfamily a, member 1
1.309 0.388 2.351 nervous system development
66042 Sostdc1 sclerostin domain containing 1 0.725 -0.464 -1.768 cell communication
20742 Spnb2 spectrin beta 2 1.729 0.790 2.855 cell communication; receptor 
binding and activity
114716 Spred2 sprouty-related, EVH1 domain 
containing 2
1.514 0.598 2.653 cell communication
21961 Tns1 tensin 1 1.505 0.590 2.245 cell communication
22370 Vtn vitronectin 0.778 -0.362 -1.925 cell adhesion
22371 Vwf Von Willebrand factor homolog 0.715 -0.484 -2.099 cell adhesion
57750 Wdr12 WD repeat domain 12 1.391 0.476 2.446 cell communication
232341 Wnk1 WNK lysine deficient protein kinase 1 1.844 0.883 2.947 cell communication
22772 Zic2 Zinc finger protein of the cerebellum 2 1.941 0.957 3.062 nervous system development
Table 4: Significantly regulated genes in mono-transgenic ADAM10 mice in relation to FVB/N wild-type mice (Continued)BMC Genomics 2009, 10:66 http://www.biomedcentral.com/1471-2164/10/66
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regulated genes code for inflammation-associated mem-
bers of the S100 protein family (S100a8 and S100a9).
In ADAM10/APP[V717I] mice, 43 AD genes (7% of 592
genes), and in dnADAM10/APP[V717I] mice, 30 AD genes
(5% of 600 genes) were altered in expression (Fig. 5). The
relatively small number of ADAM10-regulated AD genes
in double-transgenic mice probably reflects brain dissec-
tion at the age of five months, before plaque formation
begins. In all transgenic lines, we did not detect differ-
ences in the expression of presenilins 1 and 2. Bace1 was
slightly upregulated (25%) in dnADAM10/APP[V717I]
mice. The Aβ-degrading enzymes neprilysin (Mme) and
insulin-degrading enzyme (Ide) were also not regulated in
mono-transgenic mice. Solely, in ADAM10/APP[V717I]
mice, Ide was slightly down-regulated (Additional file 1,
Table S3).
In order to examine an influence of sex, a separate ChipIn-
spector analysis restricted to the 600 most up- and down-
regulated genes was performed with samples from both
female and male double-transgenic mice (Tab. 9, 10). The
gene lists of female and male double-transgenic mice were
then compared to the GeneCards AD gene list. The per-
centages of altered AD-related genes in female double-
transgenic ADAM10/APP[V717I]  and dnADAM10/
APP[V717I]female mice are similar to the numbers found in
male ADAM10/APP[V717I]and dnADAM10/APP[V717I] mice
(Fig. 6). Thus, sexual dimorphism does not cause severe
differences in ADAM10-dependent expression of AD-
related genes. One exception was the insulin-like growth
factor (Igf1), which was downregulated in female
dnADAM10/APP[V717I] mice (0.65; FDR = 1.3%), but not
in the corresponding male animals (1.17; FDR = 1.8).
Genes regulated through APP[V717I] overexpression
To determine the effect of APP[V717I] overexpression on
gene regulation in transgenic mice, we compared
APP[V717I]  mice with FVB/N mice, ADAM10/APP[V717I]
mice with ADAM10 mice, and dnADAM10/APP[V717I]
mice with dnADAM10 mice. After background adjust-
ment and normalization with the GCRMA procedure, a
Venn diagram of genes regulated in the transgenic mice
was generated (Fig. 7). The overlap of the three groups
represents 617 genes regulated by APP[V717I] overexpres-
sion, independent of the strain background. This high
Table 5: Significantly regulated genes in mono-transgenic dnADAM10 mice in relation to FVB/N wild-type mice
Gene ID Gene symbol Description Fold change log ratio d-value Functional groups
22589 Atrx alpha thalassemia/mental retardation 
syndrome X-linked homolog (human)
1.392 0.477 1.533 nervous system development
109880 Braf Braf transforming gene 0.568 -0.815 -5.060 cell communication
54598 Calcrl calcitonin receptor-like 0.626 -0.675 -2.137 cell communication
12322 Camk2a calcium/calmodulin-dependent protein 
kinase II alpha
0.686 -0.544 -2.523 cell communication; receptor 
binding and activity; synapse
12772 Ccr2 chemokine (C-C motif) receptor 2 0.724 -0.465 -1.783 cell communication
16149 Cd74 CD74 antigen (invariant polypeptide of 
major histocompatibility complex, class II 
antigen-associated)
0.737 -0.441 -2.329 cell communication; cell death
13175 Dcamkl1 doublecortin and calcium/calmodulin-
dependent protein kinase-like 1
1.501 0.586 1.610 nervous system development
12140 Fabp7 fatty acid-binding protein 7 1.691 0.758 2.107 nervous system development
14281 Fos FBJ osteosarcoma oncogene 0.669 -0.58 -1.805 nervous system development
14417 Gad2 glutamic acid decarboxylase 2 1.422 0.508 1.683 cell communication; neuron 
projection; synapse
14674 Gna13 guanine nucleotide binding protein, alpha 13 1.353 0.436 1.639 cell communication
14682 Gnaq guanine nucleotide binding protein, alpha q 
polypeptide
1.323 0.404 1.621 cell communication; nervous 
system development; synapse
15557 Htr1f 5-hydroxytryptamine (serotonin) receptor 
1F
1.363 0.447 1.539 cell communication
16594 Klc2 kinesin light chain 2 0.789 -0.341 -1.485 neuron projection
207911 Mchr1 melanin-concentrating hormone receptor 1 0.718 -0.477 -3.057 cell communication
17260 Mef2c myocyte enhancer factor 2C 1.433 0.519 1.507 nervous system development
18823 Plp1 proteolipid protein (myelin) 1 1.358 0.442 1.565 cell communication; nervous 
system development;
19293 Pvalb parvalbumin 0.847 -0.24 -1.493 neuron projection
19317 Qk quaking 1.312 0.392 1.522 cell communication; nervous 
system development
54409 Ramp2 receptor (calcitonin) activity modifying 
protein 2
1.604 0.682 1.623 cell communication
19736 Rgs4 regulator of G-protein signaling 4 1.339 0.421 1.843 cell communication
20202 S100a9 S100 calcium binding protein A9 0.696 -0.522 -2.181 cell communicationBMC Genomics 2009, 10:66 http://www.biomedcentral.com/1471-2164/10/66
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Table 6: Significantly regulated genes in double-transgenic ADAM10/APP[V717I] mice in relation to mono-transgenic APP[V717I] mice
Gene ID Gene symbol Description Fold change log ratio d-value Functional groups
56215 Acin1 apoptotic chromatin condensation inducer 1 0.795 -0.331 -1.955 cell communication; cell death
329910 Acot11 acyl-CoA thioesterase 11 0.812 -0.301 -1.620 cell communication
432530 Adcy1 adenylate cyclase 1 0.810 -0.304 -1.880 cell communication; receptor binding 
and activity
68465 Adipor2 adiponectin receptor 2 0.781 -0.357 -1.868 cell communication
11540 Adora2a adenosine A2a receptor 1.294 0.372 2.210 cell communication; synapse
11735 Ank3 ankyrin 3, epithelial 1.344 0.427 2.159 cell communication; nervous system 
development; synapse
11787 Apbb2 amyloid beta (A4) precursor protein-binding, family 
B, member 2
0.788 -0.344 -2.018 cell communication; cell death; nervous 
system development
226548 Aph1a anterior pharynx defective 1a homolog 
(C. elegans)
0.807 -0.309 -1.879 cell communication
76117 Arhgap15 Rho GTPase activating protein 15 1.275 0.351 2.139 cell communication
76294 Asb5 ankyrin repeat and SOCs box-containing protein 5 1.254 0.327 2.079 cell communication
98660 Atp1a2 ATPase, Na+/K+ transporting, alpha 2 polypeptide 0.820 -0.287 -1.746 cell communication; synapse
12043 Bcl2 B-cell leukemia/lymphoma 2 0.815 -0.295 -1.741 cell communication; cell death
72567 Bclaf1 BCL2-associated transcription factor 1 1.326 0.407 2.183 cell death
12122 Bid BH3 interacting domain death agonist 1.291 0.369 2.278 cell death
109880 Braf Braf transforming gene 0.812 -0.301 -1.837 cell communication
12227 Btg2 B-cell translocation gene 2, anti-proliferative 1.342 0.424 2.357 cell death
12300 Cacng2 calcium channel, voltage-dependent, gamma 
subunit 2
0.803 -0.316 -1.872 cell communication
12325 Camk2g calcium/calmodulin-dependent protein kinase II 
gamma
0.810 -0.304 -1.711 receptor binding and activity
12319 Car8 carbonic anhydrase 8 0.785 -0.349 -1.679 cell communication
12361 Cask calcium/calmodulin-dependent serine protein kinase 
(MAGUK family)
0.832 -0.265 -1.689 receptor binding and activity; synapse
226751 Cdc42bpa Cdc42 binding protein kinase alpha 1.288 0.365 2.130 cell communication
12575 Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) 0.779 -0.36 -2.004 cell death
235415 Cplx3 complexin 3 1.276 0.352 2.294 cell communication; synapse
12955 Cryab crystallin, alpha B 0.744 -0.427 -2.161 cell communication
12977 Csf1 colony stimulating factor 1 (macrophage) 0.822 -0.282 -1.717 cell adhesion; cell communication; 
receptor binding and activity
27373 Csnk1e casein kinase 1, epsilon 0.791 -0.338 -2.160 cell communication
13000 Csnk2a2 casein kinase 2, alpha prime polypeptide 0.801 -0.321 -1.909 cell communication
16007 Cyr61 cysteine rich protein 61 1.298 0.376 2.213 receptor binding and activity
54722 Dfna5h deafness, autosomal dominant 5 homolog (human) 0.803 -0.316 -1.714 cell communication
330938 Dixdc1 DIX domain containing 1 0.825 -0.278 -1.770 cell communication
50768 Dlc1 deleted in liver cancer 1 0.794 -0.332 -1.894 cell communication
13430 Dnm2 dynamin 2 0.815 -0.295 -2.004 synapse
13527 Dtna dystrobrevin alpha 1.271 0.346 2.240 synapse
13841 Epha7 Eph receptor A7 1.300 0.379 2.146 cell communication; nervous system 
development
14254 Flt1 FMS-like tyrosine kinase 1 0.787 -0.345 -2.064 cell communication
118446 Gje1 gap junction membrane channel protein epsilon 1 1.349 0.432 2.453 cell communication;
69367 Glrx2 glutaredoxin 2 (thioltransferase) 1.252 0.324 2.066 cell communication; cell death
14682 Gnaq guanine nucleotide binding protein, alpha q 
polypeptide
0.813 -0.298 -1.776 cell communication; nervous system 
development;synapse
224792 Gpr116 G protein-coupled receptor 116 1.279 0.355 2.154 cell communication
14799 Gria1 glutamate receptor, ionotropic, AMPA1 (alpha 1) 0.776 -0.365 -1.975 synapse
14800 Gria2 glutamate receptor, ionotropic, AMPA2 (alpha 2) 0.740 -0.435 -1.907 cell communication; synapse
14804 Grid2 glutamate receptor, ionotropic, delta 2 0.806 -0.312 -1.793 synapse
14943 Gzmf granzyme F 0.801 -0.321 -1.928 cell death
15258 Hipk2 homeodomain interacting protein kinase 2 0.761 -0.394 -2.283 cell communication; cell death
26557 Homer2 homer homolog 2 (Drosophila) 0.774 -0.37 -2.144 cell communication
14828 Hspa5 heat shock 70 kD protein 5 
(glucose-regulated protein)
0.716 -0.481 -1.984 cell communication; cell death
56213 Htra1 HtrA serine peptidase 1 0.795 -0.331 -1.834 cell communication; receptor binding 
and activity
15951 Ifi204 interferon activated gene 204 1.268 0.343 2.104 cell death
16323 Inhba inhibin beta-A 0.718 -0.477 -2.551 cell death; receptor binding and activity
241226 Itga8 integrin alpha 8 1.270 0.345 2.112 cell adhesion; cell communication
16419 Itgb5 integrin beta 5 0.832 -0.265 -1.649 cell adhesion; cell communication
16443 Itsn1 intersectin 1 (SH3 domain protein 1A) 0.826 -0.275 -1.839 cell communication
22343 Lin7c lin-7 homolog C (C. elegans) 0.831 -0.267 -1.652 cell communication; synapse
330814 Lphn1 latrophilin 1 0.803 -0.316 -1.934 cell communication
16998 Ltbp3 latent transforming growth factor beta binding 
protein 3
1.291 0.368 2.202 cell communication; receptor binding 
and activity
17762 Mapt microtubule-associated protein tau 0.727 -0.459 -2.312 nervous system development
17118 Marcks myristoylated alanine rich protein kinase C substrate 0.799 -0.324 -1.815 receptor binding and activity
13728 Mark2 MAP/microtubule affinity-regulating kinase 2 0.817 -0.291 -1.922 cell communication
17193 Mbd4 methyl-CpG binding domain protein 4 0.818 -0.289 -1.753 cell deathBMC Genomics 2009, 10:66 http://www.biomedcentral.com/1471-2164/10/66
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52065 Mfhas1 malignant fibrous histiocytoma amplified sequence 1 0.759 -0.398 -2.297 cell communication
59030 Mkks McKusick-Kaufman syndrome protein 0.749 -0.416 -2.427 cell communication
17346 Mknk1 MAP kinase-interacting serine/threonine kinase 1 1.273 0.348 2.113 cell communication
17748 Mt1 metallothionein 1 0.807 -0.31 -1.974 cell communication
17750 Mt2 metallothionein 2 0.780 -0.359 -2.141 cell communication
17909 Myo10 myosin X 0.824 -0.28 -1.751 cell communication
17918 Myo5a myosin Va 1.309 0.389 2.105 cell communication; receptor binding 
and activity; synapse
17984 Ndn necdin 1.315 0.395 2.209 cell communication; nervous system 
development
192167 Nlgn1 neuroligin 1 1.381 0.466 2.470 cell communication; nervous system 
development; synapse
18125 Nos1 nitric oxide synthase 1, neuronal 0.795 -0.331 -1.953 cell communication; receptor binding 
and activity; synapse
225872 Npas4 neuronal PAS domain protein 4 1.355 0.438 2.375 cell communication
18212 Ntrk2 neurotrophic tyrosine kinase, receptor, type 2 0.797 -0.327 -1.978 cell communication; synapse
18378 Omp olfactory marker protein 0.790 -0.34 -1.907 cell communication
18389 Oprl1 opioid receptor-like 1 1.330 0.411 2.066 cell communication
18577 Pde4a phosphodiesterase 4A, cAMP specific 0.812 -0.301 -1.903 cell communication
18578 Pde4b phosphodiesterase 4B, cAMP specific 0.812 -0.301 -1.586 cell communication
18583 Pde7a phosphodiesterase 7A 0.830 -0.268 -1.656 cell communication
14827 Pdia3 protein disulfide isomerase associated 3 0.812 -0.3 -1.829 cell death
74055 Plce1 phospholipase C, epsilon 1 0.807 -0.309 -1.923 cell communication
67916 Ppap2b phosphatidic acid phosphatase type 2B 0.784 -0.351 -2.088 cell communication
170826 Ppargc1b peroxisome proliferative activated receptor, gamma, 
coactivator 1 beta
0.749 -0.417 -2.262 cell communication
333654 Ppp1r13l protein phosphatase 1, regulatory (inhibitor) 
subunit 13 like
0.820 -0.287 -1.903 cell death
73728 Psd pleckstrin and Sec7 domain containing 1.291 0.368 2.130 cell communication
19246 Ptpn1 protein tyrosine phosphatase, non-receptor type 1 0.754 -0.407 -2.217 cell communication
19268 Ptprf protein tyrosine phosphatase, receptor type, F 0.815 -0.296 -1.789 cell communication
19334 Rab22a RAB22A, member RAS oncogene family 0.817 -0.292 -1.773 cell communication
19337 Rab33a RAB33A, member of RAS oncogene family 1.276 0.352 2.165 cell communication
19340 Rab3d RAB3D, member RAS oncogene family 0.792 -0.337 -1.964 cell communication
19415 Rasal1 RAS protein activator like 1 (GAP1 like) 1.312 0.392 2.203 cell communication
17252 Rdh11 retinol dehydrogenase 11 1.300 0.378 2.172 cell communication
56533 Rgs17 regulator of G-protein signaling 17 1.309 0.388 2.141 cell communication
56470 Rgs19 regulator of G-protein signaling 19 1.275 0.35 2.124 cell communication
19893 Rpgr retinitis pigmentosa GTPase regulator 1.322 0.403 2.232 cell communication
77945 Rpgrip1 retinitis pigmentosa GTPase regulator interacting 
protein 1
0.784 -0.351 -1.946 cell communication
110876 Scn2a1 sodium channel, voltage-gated, type II, alpha 1 0.798 -0.325 -1.848 cell communication; cell death
58234 Shank3 SH3/ankyrin domain gene 3 0.779 -0.361 -2.189 cell communication; cell death
27401 Skp2 S-phase kinase-associated protein 2 (p45) 1.278 0.354 2.111 cell death
65962 Slc9a3r2 solute carrier family 9 (sodium/hydrogen 
exchanger), isoform 3 regulator 2
0.816 -0.293 -1.665 cell communication
17128 Smad4 MAD homolog 4 (Drosophila) 0.802 -0.318 -1.838 cell communication
20411 Sorbs1 sorbin and SH3 domain containing 1 0.779 -0.361 -1.938 cell adhesion; cell communication
20692 Sparc secreted acidic cysteine rich glycoprotein 0.756 -0.403 -2.405 cell communication
114715 Spred1 sprouty protein with EVH-1 domain 1, related 
sequence
0.796 -0.329 -1.928 cell communication
114716 Spred2 sprouty-related, EVH1 domain containing 2 0.776 -0.365 -1.933 cell communication
14270 Srgap2 SLIT-ROBO Rho GTPase activating protein 2 0.825 -0.278 -1.778 cell communication
20848 Stat3 signal transducer and activator of transcription 3 0.808 -0.308 -1.710 cell communication
20913 Stxbp4 syntaxin binding protein 4 0.786 -0.347 -2.069 cell communication
240725 Sulf1 sulfatase 1 0.833 -0.264 -1.811 cell death
104015 Synj1 synaptojanin 1 1.366 0.45 2.207 cell communication; synapse
24071 Synj2bp synaptojanin 2 binding protein 0.752 -0.411 -2.093 cell communication
21415 Tcf3 transcription factor 3 0.799 -0.323 -1.978 cell communication
21416 Tcf7l2 transcription factor 7-like 2, T-cell specific, 
HMG-box
1.352 0.435 2.231 cell communication
110595 Timp4 tissue inhibitor of metalloproteinase 4 0.797 -0.328 -1.646 cell communication; synapse
22031 Traf3 Tnf receptor-associated factor 3 0.812 -0.3 -1.800 cell communication; cell death
94090 Trim9 tripartite motif protein 9 0.759 -0.397 -1.905 cell communication; synapse
22421 Wnt7a wingless-related MMTV integration site 7A 0.827 -0.274 -1.758 cell communication; nervous system 
development; synapse
78889 Wsb1 WD repeat and SOCS box-containing 1 1.288 0.365 2.069 cell communication
22627 Ywhae tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, epsilon 
polypeptide
1.319 0.399 2.098 cell communication
235320 Zbtb16 zinc finger and BTB domain containing 16 0.776 -0.366 -1.759 cell death
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Table 7: Significantly regulated genes in double-transgenic dnADAM10/APP[V717I] mice in relation to mono-transgenic APP[V717I] mice
Gene ID Gene symbol Description Fold change log ratio d-value Functional groups
268860 Abat 4-aminobutyrate aminotransferase 1.503 0.588 3.791 cell communication; synapse
67269 Agtpbp1 ATP/GTP binding protein 1 1.397 0.482 3.311 cell communication; synapse
226548 Aph1a anterior pharynx defective 1a 
homolog (C. elegans)
0.724 -0.466 -3.127 cell communication
11938 Atp2a2 ATPase, Ca++ transporting, cardiac 
muscle, slow twitch 2
1.456 0.542 3.900 cell communication
140494 Atp6v0a4 ATPase, H+ transporting, lysosomal 
V0 subunit A4
0.762 -0.392 -2.972 cell communication
12122 Bid BH3 interacting domain death agonist 1.381 0.466 3.765 cell death
12293 Cacna2d1 calcium channel, voltage-dependent, 
alpha2/delta subunit 1
1.460 0.546 4.086 cell communication
20303 Ccl4 chemokine (C-C motif) ligand 4 0.755 -0.405 -2.995 receptor binding and activity
12772 Ccr2 chemokine (C-C motif) receptor 2 0.648 -0.625 -3.824 cell communication
12955 Cryab crystallin, alpha B 0.711 -0.492 -3.095 cell communication
12977 Csf1 colony stimulating factor 1 
(macrophage)
0.767 -0.383 -2.920 cell adhesion; cell communication; 
receptor binding and activity
56066 Cxcl11 chemokine (C-X-C motif) ligand 11 0.760 -0.395 -2.953 receptor binding and activity
20315 Cxcl12 chemokine (C-X-C motif) ligand 12 1.373 0.457 3.359 receptor binding and activity
224997 Dlgap1 discs, large (Drosophila) homolog-
associated protein 1
1.417 0.503 3.720 cell communication; synapse
13527 Dtna dystrobrevin alpha 1.338 0.42 3.294 synapse
23882 Gadd45g growth arrest and DNA-damage-
inducible 45 gamma
1.371 0.455 3.534 cell death
14943 Gzmf granzyme F 0.745 -0.424 -3.031 cell death
215114 Hip1 huntingtin interacting protein 1 0.772 -0.373 -2.971 cell death
15257 Hipk1 homeodomain interacting protein 
kinase 1
0.726 -0.461 -3.122 cell death
15452 Hprt1 hypoxanthine guanine 
phosphoribosyl transferase 1
1.375 0.459 3.326 cell communication; cell death; 
synapse
215257 Il1f9 interleukin 1 family, member 9 0.706 -0.503 -3.808 receptor binding and activity
16323 Inhba inhibin beta-A 0.744 -0.426 -2.892 cell death; receptor binding and 
activity
16325 Inhbc inhibin beta-C 0.715 -0.483 -3.508 receptor binding and activity
16179 Irak1 interleukin-1 receptor-associated 
kinase 1
1.431 0.517 3.661 receptor binding and activity
80782 Klrb1d killer cell lectin-like receptor 
subfamily B member 1D
0.735 -0.444 -3.340 cell death
16818 Lck lymphocyte protein tyrosine kinase 0.698 -0.519 -3.204 cell communication; cell death
17248 Mdm4 transformed mouse 3T3 cell double 
minute 4
1.377 0.462 3.303 cell death
59030 Mkks McKusick-Kaufman syndrome 
protein
0.723 -0.468 -3.503 cell communication
17910 Myo15 myosin XV 0.753 -0.41 -2.883 cell communication
18125 Nos1 nitric oxide synthase 1, neuronal 0.741 -0.432 -3.040 cell communication; receptor binding 
and activity; synapse
21907 Nr2e1 nuclear receptor subfamily 2, group 
E, member 1
0.702 -0.511 -3.426 cell communication; cell death
57270 Olfr1508 olfactory receptor 1508 0.735 -0.444 -3.162 cell communication
18378 Omp olfactory marker protein 0.756 -0.403 -2.860 cell communication
170677 Pcdh21 protocadherin 21 0.614 -0.703 -3.902 cell communication
14827 Pdia3 protein disulfide isomerase 
associated 3
0.745 -0.424 -2.866 cell death
18821 Pln phospholamban 0.741 -0.432 -3.181 cell communication
333654 Ppp1r13l protein phosphatase 1, regulatory 
(inhibitor) subunit 13 like
0.733 -0.449 -3.361 cell death
54189 Rabep1 rabaptin, RAB GTPase binding 
effector protein 1
1.377 0.462 3.307 cell death; receptor binding and 
activity
17252 Rdh11 retinol dehydrogenase 11 1.374 0.458 3.317 cell communication
212541 Rho rhodopsin 0.762 -0.393 -3.078 cell communication
19877 Rock1 Rho-associated coiled-coil containing 
protein kinase 1
1.402 0.487 3.841 cell deathBMC Genomics 2009, 10:66 http://www.biomedcentral.com/1471-2164/10/66
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number of genes altered by APP[V717I] expression demon-
strates the strong influence of human APP[V717I] overex-
pression in the AD mouse model used.
AD-related genes that were regulated in double-trans-
genic, but not in mono-transgenic mice include microtu-
bule-associated protein tau (Mapt) (Tab. 6; Tab. S3) and
the ionotropic glutamate receptors AMPA 1 (Gria 1) and
AMPA 2 (Gria 2) (Tab. 6; Tab. S3).
Confirmation of microarray data
For validation of the results obtained by microarray anal-
ysis, real-time RT-PCR was applied on the original RNA
samples (Fig. 8 and 9). Changes in gene expression levels
of selected transcripts were normalized to the gene expres-
sion of GAPDH, which was not regulated in our trans-
genic mouse strains.
In the microarray analyses, the calcium-binding proteins
(S100a8 and S100a9) were found to be downregulated in
ADAM10 and dnADAM10 mice. Both genes are associated
with various inflammatory processes including Alzhe-
imer's disease [25]. By using real-time RT-PCR, significant
downregulation of S100a8 and S100a9 was confirmed
(Fig. 8B and 9D). Additionally, quantification of dimers
of S100a8 and a9 (calprotectin) by ELISA revealed a slight
reduction in both transgenic mouse lines (Fig. 10C)
which is in accordance with the findings for mRNA levels.
The decrease of about 10 to 15% of calprotectin as com-
pared to wild-type mice was not statistically significant
which might be due to ELISA-specific detection of het-
erodimers. We cannot exclude that changes concerning
both monomeric proteins might be more substantial, but
a detection of the monomeric form of S100a9 by Western
blotting failed as a consequence of its low expression
level.
Fatty acid-binding protein 7 (Fabp7), which is elevated in
Down syndrome fetal brains [26], was found to be upreg-
ulated in dnADAM10 mice by microarray analysis. A sig-
nificantly increased Fabp7 expression was confirmed in
dnADAM10 mice by real-time RT-PCR. As observed by
real-time RT-PCR, expression of Fabp7 was slightly
reduced in ADAM10 mice, but this effect did not reach a
significant level (Fig. 8E). Fabp7 protein expression was
analyzed in the soluble protein fraction from brains of
mono-transgenic mice by Western blotting. While
ADAM10 had no significant effect on Fabp7 expression,
the dominant-negative form dnADAM10 increased the
amount of the Fabp7 protein (Fig. 10A/B), which is in
accordance with the results obtained by microarray and
PCR analysis.
Neuroligin 1, a postsynaptic cell-adhesion molecule of
excitatory synapses, plays a role in neuronal differentia-
tion and axogenesis [27]. In microarray analyses, neuroli-
gin 1 gene expression was induced in ADAM10 mice. This
19893 Rpgr retinitis pigmentosa GTPase 
regulator
1.361 0.445 3.332 cell communication
110876 Scn2a1 sodium channel, voltage-gated, type 
II, alpha 1
1.393 0.478 3.500 cell communication; cell death
58234 Shank3 SH3/ankyrin domain gene 3 0.769 -0.379 -2.946 cell communication; cell death
22293 Slc45a2 solute carrier family 45, member 2 0.731 -0.453 -3.211 cell communication
20682 Sox9 SRY-box containing gene 9 0.754 -0.408 -3.089 cell death
20977 Syp synaptophysin 1.448 0.534 3.608 cell communication; synapse
20979 Syt1 synaptotagmin I 1.397 0.482 3.587 cell communication; synapse
21823 Th tyrosine hydroxylase 0.761 -0.394 -2.993 cell communication; synapse
94090 Trim9 tripartite motif protein 9 0.716 -0.481 -2.963 cell communication; synapse
59025 Usp14 ubiquitin specific peptidase 14 1.383 0.468 3.342 cell communication; synapse
16963 Xcl1 chemokine (C motif) ligand 1 0.749 -0.416 -3.003 receptor binding and activity
Table 7: Significantly regulated genes in double-transgenic dnADAM10/APP[V717I] mice in relation to mono-transgenic APP[V717I] mice 
Table 8: Substrates of ADAM10 [43] which are not regulated in mono-transgenic mice within the parameters given in the Methods 
section
Substrate groups Symbol name of Mouse Gene
CNS substrates of ADAM10 App, Aplp2, Prnp, Efna2, L1cam, Cdh2, Pcdhg, Dll1, Notch1
Substrates of ADAM10 in inflammation Cx3cl1, Cxcl16, Cdh5, F11r (JAM-A), Il6r, Fasl, Tnfrsf8 (CD30), Cd44
Growth factors and receptors cleaved by ADAM10 Egfr, Egf, Btc, Erbb2BMC Genomics 2009, 10:66 http://www.biomedcentral.com/1471-2164/10/66
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tendency, although without reaching significance, was
also confirmed in real-time RT-PCR (Fig. 8C).
Other proteins identified by gene profiling and associated
with Alzheimer disease are the low density lipoprotein
receptor-related protein 1 (Lrp1) [28], the very low den-
sity lipoprotein receptor (Vldlr) [29], the microtubule-
associated protein tau (Mapt) [30] and the ionotropic
glutamate receptors AMPA1 and AMPA2 (Gria1 and
Gria2) [31]. Downregulation of Lrp1 by ADAM10, as
observed in the chip analyses, was not confirmed by real-
time RT-PCR (results not shown). For Vldlr, we found by
real-time RT-PCR a significant downregulation in
ADAM10/APP[V717I]  mice, but its upregulation in
dnADAM10/APP[V717I] mice, as detected with the microar-
ray, could not be confirmed (Fig. 9B).
By real-time RT-PCR, the microtubule-associated protein
tau was shown to be significantly downregulated in both
double-transgenic mouse lines (Fig. 9E). Also in the case
of the ionotropic glutamate receptors AMPA1 (Gria1) and
AMPA2 (Gria 2), real-time RT-PCR confirmed the results
of the microarray analyses: both genes are downregulated
in ADAM10/APP[V717I] mice (Fig. 9C and 9D).
Discussion
Increasing the α-secretase cleavage of APP represents a
plausible strategy for the treatment of Alzheimer disease,
because via this route it is possible to decrease the concen-
tration of neurotoxic Aβ peptides and to increase the
amount of neuroprotective APPsα simultaneously.
The aim of this study was to investigate the influence of
increased amounts of ADAM10 proteins on gene expres-
sion in the mouse CNS. To this end, we analyzed trans-
genic mice either overexpressing catalytically active
ADAM10, or a dominant-negative mutant of ADAM10
(dnADAM10) which is able to inhibit endogenous mouse
enzymes with α-secretase activity [10,12]. An additional
reason for investigation of dnADAM10 mice is deter-
mined by the multi-domain structure of ADAMs because
specific biological functions have been assigned to protein
domains outside the catalytic centre of ADAMs [15].
In ADAM10 mice, more genes were regulated than in
dnADAM10 animals; this indicates that, due to the many
substrates of ADAM10, an increase in their cleavage prod-
ucts might change the expression of genes involved in cell
communication and synaptic transmission. No change,
however, was detected in the expression of the substrates
as a feedback reaction.
In all transgenic mice the endogenous ADAM10 level was
not influenced through overexpression of ADAM10 or its
inactive variant as revealed by real-time RT-PCR. Also the
other ADAM family members Adam9 and Adam17/TACE
were not regulated differentially in the investigated trans-
genic mice, thus indicating that a reduced α-secretase
activity as observed in dnADAM10 mice [12] was not
compensated by the induction of gene expression of other
potential α-secretases.
Since ADAM10 has been implicated in Notch signaling
[11,32], we investigated this pathway. On the RNA level,
we found no regulation of Notch-1 in mono- and double-
transgenic mice at the age of 5 months: expression of the
Notch target gene Hes5 was only slightly changed in
mono-transgenic ADAM10 mice. This is in accordance
with earlier real-time RT-PCR experiments, where no sig-
nificant difference was found in Hes5 transcription levels
between adult mice overexpressing ADAM10 and non-
transgenic mice [12]. This lack of influence on Notch sig-
naling is probably due to the late stage of analysis, since
we found small but significant effects of ADAM10 on
Hes5 mRNA levels in transgenic mice aged 15 days.
ADAM10 has been reported to mediate cadherin shed-
ding, β-catenin translocation and expression of β-catenin
target genes [33,34]. In double-transgenic dnADAM10/
APP[V717I]  mice various cadherins (Cdh8, Cdh10 and
Cdh13), β-catenin (Ctnnb1), several Wnts (Wnt4, Wnt7a
and Wnt9a) and Jun kinase (Jun) were upregulated (about
30%). The upregulation of these genes might represent a
compensatory mechanism to by-pass a reduced catalytic
activity of ADAM10 and β-catenin signaling. In mice over-
expressing active ADAM10, no significant changes of β-
catenin target genes, for example c-myc and cyclin D1,
were found.
Hes5 mRNA levels in 15 days old ADAM10 transgenic mice Figure 4
Hes5 mRNA levels in 15 days old ADAM10 trans-
genic mice. Brains of 15 days old FVB/N (Wt), ADAM10 
(AD) or ADAM10 dominant negative mutant (dn) overex-
pressing mice were analyzed for the amount of the Notch-1 
target gene Hes5 mRNA. Quantification was performed by 
real-time RT-PCR. Values represent means ± SEM of four 
mice per group normalized to GAPDH mRNA (one way 
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Also for other ADAM10 substrates like L1cam, proteins
involved in inflammation like Fasl, and for growth factor
receptors like Egfr (see also table 8), we could not demon-
strate any alteration.
Most genes in ADAM10 and ADAM10/APP[V717I] mice
were found to be altered in the pathway of cell communi-
cation, followed by genes in categories of nervous system
development and synaptic junction and transmission
(Tab. 4, 5, 6, 7). One example for a regulated gene in the
category of cell communication and synaptic function is
the calcium/calmodulin-dependent protein kinase II
alpha (Camk2α), one of the most abundant kinases in the
brain, which is involved in long term potentiation.
Camk2α was upregulated in ADAM10 mice, and down-
regulated in dnADAM10. Another gene of cell communi-
cation and synaptic function is neuroligin (Nlgn1), a
brain-specific acetylcholinesterase homologous protein,
which was upregulated in ADAM10/APP[V717I] mice (Fig.
9F). This component of excitatory synapses plays a role in
neuronal differentiation and axogenesis [27]. An increase
in cortical synaptogenesis as found by Bell et al. in
ADAM10 mice [14], was confirmed through upregulation
of the glutamate receptor Gria3 and the glutamic acid
decarboxylase 2 (Gad2) as well as the GABA-A receptor
subunit alpha 4 (Gabra4).
Downregulation of the ionotropic glutamate receptors
AMPA1 (Gria1) and AMPA2 (Gria2) as observed in our
microarray study was confirmed by real-time RT-PCR:
reduced mRNA levels of Gria1 and Gria2 were detected in
ADAM10/APP[V717I] mice. The downregulation of these
two genes possibly depends on overexpression of
APP[V717I] as described before [35,36].
The number of regulated genes involved in the develop-
ment of AD was relatively small in the brains of double-
transgenic ADAM10/APP[V717I] and dnADAM10/APP[V717I]
mice, and almost equivalent to mono-transgenic
ADAM10 or dnADAM10 mice (Fig. 5). We did not detect
differences in most genes directly involved in APP
processing; but reduction of α-secretase activity induced a
slight upregulation of Bace1 in dnADAM10/APP[V717I]
mice.
Comparative GCRMA analysis demonstrated the strong
influence of human APP[V717I] overexpression on gene
expression in double-transgenic mice. Tau (Mapt) was
directly downregulated through APP[V717I] overexpression
in ADAM10/APP[V717I]  versus ADAM10 mice. Altered
expression of AD-related genes was independent of sex,
with one exception: insulin-like growth factor 1 (Igf-1),
which has been implicated in Alzheimer pathology
[37,38], was downregulated in double-transgenic female
dnADAM10/APP[V717I] mice.
By microarray analysis, we observed in mono-transgenic
mice a downregulation of members of the S100 protein
family, small calcium-binding proteins responsible for a
wide range of intra- and extracellular functions [39].
Alzheimer disease genes in mono- and double-transgenic  mice Figure 5
Alzheimer disease genes in mono- and double-trans-
genic mice. Differentially expressed genes of ADAM10 ver-
sus FVB/N with FDR 0.5 (355 genes), of dnADAM10 versus 
FVB/N with FDR 0.5 (143 genes), of ADAM10/APP[V717I] ver-
sus APP[V717I] with FDR 0.0 (592 genes) and of dnADAM10/
APP[V717I] versus APP[V717I] with FDR 0.0, restricted to 300 
up- and 300 downregulated genes (600 genes), were com-
pared to AD genes (934 genes) from GeneCards (Weizmann 
Institute of Science, Version 2.36). In ADAM10 versus FVB/N 
25 AD genes (7% of 355 genes), in dnADAM10 versus FVB/N 
13 AD genes (9% of 143 genes), in ADAM10/APP[V717I]versus 
APP[V717I] 43 AD genes (7% of 592 genes) and in dnADAM10/







































Table 9: Numbers of significantly regulated genes in male double-transgenic mice restricted by the given d-values.
Mouse Genome 430 2.0 Array (Affymetrix)
45 000 probe sets, 39 000 transcripts, 34 000 characterized
male ADAM10/APP[V717I] versus APP[V717I]
600 genes, FDR = 1.3%
male dnADAM10/APP[V717I] versus APP[V717I]
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S100a8 and S100a9 were expressed to a lower extent in
ADAM10 and dnADAM10 mice. PCR analysis and ELISA
confirmed this effect (Fig. 8B and 8D, Figure 10C).
S100a8 and S100a9 form the dimer calprotectin which is
a marker for inflammation [40]. Immunohistochemical
analysis recently showed S100A9 in association with the
neuropathological hallmarks of sporadic and familiar AD:
it was found in senile plaques, in activated glia cells and
in neurons with neurofibrillary tangle morphology [25].
The downregulation of S100a9 by both ADAM10 and
dnADAM10 overexpression is probably mediated by their
common domains (the disintegrin and cystein-rich
domain as well as the C-terminus).
A member of the fatty acid-binding proteins (Fabp7) was
regulated by ADAM10 in mono-transgenic mice. Fabp7,
also named brain lipid-binding protein (B-Fabp), is local-
ized in the cytoplasm and in the nucleus, and is involved
in the uptake, storage and/or delivery of fatty acids and
retinoids into the nucleus [41]. Fabp7 is mainly expressed
in radial glial cells, and is necessary for proper migration
of immature neurons to cortical layers. Increased amounts
of Fabp7 in the brains of individuals with Down syn-
drome suggest that higher concentrations of Fabp7 con-
tribute to brain abnormalities and mental retardation
[26]. We observed a significant upregulation of Fabp7
mRNA and protein in dnADAM10 mice. Since in Down
syndrome patients α-secretase activity significantly
decreases with age [42], our results provide a connection
between inhibition of α-secretase (in our study by
dnADAM10) and upregulation of Fabp7.
Venn diagram of regulated genes in investigated mouse lines  after CARMA-analysis (BH<0.005) Figure 7
Venn diagram of regulated genes in investigated 
mouse lines after CARMA-analysis (BH<0.005). Venn 
diagram of APP[V717I]versus FVB/N (A), ADAM10/APP[V717I] 
versus ADAM10 (B) und dnADAM10/APP[V717I] versus 
dnADAM10 (C), generated by a custom-written Perl-script 
showing the effect of APP[V717I] overexpression in double-
transgenic mice. The numbers in the spaces of overlapping 
circles represent the number of transcripts that were 
affected in all mouse groups. The numbers in the outer por-
tion of each circle represent the number of transcripts that 
were exclusively affected in two mouse groups.
Alzheimer disease genes in female and male double-trans- genic mice Figure 6
Alzheimer disease genes in female and male double-
transgenic mice. Differentially expressed genes of female 
and male ADAM10/APP[V717I] versus APP[V717I] and of 
dnADAM10/APP[V717I]versus APP[V717I] with FDR 1.3, 
restricted to the 600 best up- and downregulated genes 
were analyzed for AD genes (934 genes) from GeneCards 
(Weizmann Institute of Science, Version 2.36). In female 
ADAM10/APP[V717I] versus APP[V717I] mice 49 AD genes (8% 
of 600 genes) and in female dnADAM10/APP[V717I] versus 
APP[V717I] animals 35 AD genes (6% of 600 genes) were found 
to be affected. In male ADAM10/APP[V717I] versus APP[V717I] 
mice 42 AD genes (7% of 600 genes) and in male 
dnADAM10/APP[V717I] versus APP[V717I] mice 31 AD genes 
(5% of 600 genes) were found to be affected. The corre-
sponding d-values are listed separately for male (Tab. 9) and 






































Table 10: Numbers of significantly regulated genes in female double-transgenic mice restricted by the given d-values
Mouse Genome 430 2.0 Array (Affymetrix)
45 000 probe sets, 39 000 transcripts, 34 000 characterized
female ADAM10/APP[V717I] versus APP[V717I]
600 genes, FDR = 1.3%
female dnADAM10/APP[V717I] versus APP[V717I]
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Analyses of gene expression of selected candidate genes by real-time RT-PCR in mono-transgenic mice Figure 8
Analyses of gene expression of selected candidate genes by real-time RT-PCR in mono-transgenic mice. Expres-
sion levels of individual genes in mono-transgenic mice in relation to gene expression in FVB/N wild-type mice. Shown are the 
results from RT-PCR and microarray analyses. Values presented: mean of fold changes ± SD of three animals. A: ADAM10; B: 
S100a8; C: Nlgn1; D: S100a9; E: Fabp7. Statistical significance was determined by using ANOVA analysis, followed by Dunnett's 
post hoc comparison (*), p ≤ 0.05; (**), p ≤ 0.001; (***), p ≤ 0.001.BMC Genomics 2009, 10:66 http://www.biomedcentral.com/1471-2164/10/66
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Analyses of gene expression of selected candidate genes by real-time RT-PCR in mono-transgenic mice Figure 8
Analyses of gene expression of selected candidate genes by real-time RT-PCR in mono-transgenic mice. Expres-
sion levels of individual genes in mono-transgenic mice in relation to gene expression in FVB/N wild-type mice. Shown are the 
results from RT-PCR and microarray analyses. Values presented: mean of fold changes ± SD of three animals. A: ADAM10; B: 
S100a8; C: Nlgn1; D: S100a9; E: Fabp7. Statistical significance was determined by using ANOVA analysis, followed by Dunnett's 
post hoc comparison (*), p ≤ 0.05; (**), p ≤ 0.001; (***), p ≤ 0.001.BMC Genomics 2009, 10:66 http://www.biomedcentral.com/1471-2164/10/66
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Analyses of gene expression of selected candidate genes by real-time RT-PCR in double-transgenic mice Figure 9
Analyses of gene expression of selected candidate genes by real-time RT-PCR in double-transgenic mice. 
Expression levels of individual genes in double-transgenic mice in relation to gene expression in APP[V717I] mono-transgenic 
mice. Shown are the results from RT-PCR and microarray analyses. Values presented: mean of fold changes ± SD of 4–6 ani-
mals. A: ADAM10; B: Vldlr; C: Gria1; D: Gria2; E: Mapt; F: Nlgn1. Statistical significance was determined by using ANOVA anal-
ysis, followed by Dunnett's post hoc comparison (*), p ≤ 0.05; (**), p ≤ 0.001; (***), p ≤ 0.001.BMC Genomics 2009, 10:66 http://www.biomedcentral.com/1471-2164/10/66
Page 22 of 24
(page number not for citation purposes)
Conclusion
This study shows that overexpression of ADAM10 or
dnADAM10 in the brain of adult mice does not lead to
drastic alteration of gene expression. In particular,
ADAM10 or dnADAM10 overexpression does not result in
an increased expression of genes coding for pro-inflam-
matory or pro-apoptotic proteins. On the contrary, over-
expression of ADAM10 and its mutant even leads to a
decreased amount of the inflammation marker calprotec-
tin (the dimer of S100a8 and S100a9).
The relatively low number of genes affected by the
ADAM10 modulation and the mild characteristic of
altered expression levels might be related to the age of the
mice we investigated. Since expression in the whole brain
was analyzed, a higher change of gene expression may
occur in single areas like the hippocampus. From other
reports it is evident that manipulation of ADAM10 in
embryonic or early ontogenic stages could have severe
side effects but therapeutic approaches concerning Alzhe-
imer's disease always will focus on adult patients. Our
results in sum therefore provide evidence that, due to its
effect on inflammation markers and on Fabp7 expression,
ADAM10 might have beneficial effects in addition to
those that are due to its α-secretase activity. These results
further support the strategy of ADAM10 upregulation as a
therapeutic approach for the treatment of AD.
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(AD): Alzheimer disease; (APP): amyloid precursor pro-
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disintegrin and metalloproteinase 10.
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Effect of Adam10 on Fabp7 and S100a8/a9 proteins in mouse  brain Figure 10
Effect of Adam10 on Fabp7 and S100a8/a9 proteins in 
mouse brain. A) Fabp7 protein expression was analyzed in 
fractions of soluble brain proteins of mono-transgenic mice 
by Western blotting (Wt: wild-type, AD: ADAM10, dn: dom-
inant negative ADAM10). As a control for antibody specifi-
city, a lysate of HEK293 cells overexpressing V5-tagged 
murine Fabp7 (19 kDa; +) was used. B) Quantification of 
Fabp7 was performed with at least 5 animals per group. Val-
ues represent mean ± SEM, and values obtained for wild-type 
animals (Wt) were set to 100% (one way ANOVA, Bonfer-
roni post-test; ns, not significant; p < 0.001, ***). C) Expres-
sion of dimeric S100a8/a9 (calprotectin) was quantified by 
ELISA in mouse brain extracts. Measured absorptions at 405 
nm were normalized to wet tissue weight (mean ± SEM; n = 
4).
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